Dr. Mark Kenneth Greenwald | |
Wayne State University School of Medicine Psychiatry and Behavioral Neurosciences Substance Abuse Research Division DirectorAppointed: 2006 Wayne State University School of Medicine Psychiatry and Behavioral Neurosciences Translational Neuroscience Program Director (Graduate Officer)Appointed: 2006 Wayne State University School of Medicine Psychiatry and Behavioral Neurosciences Human Pharmacology Laboratory ChiefAppointed: 2006 Wayne State University School of Medicine Psychiatry and Behavioral Neurosciences Promotion and Tenure Committee ChairAppointed: 2006 Wayne State University School of Medicine Psychiatry and Behavioral Neurosciences Substance Abuse Research Division Associate ProfessorAppointed: 2003 | |
QualificationsPostdoctoral Fellowship, National Institutes of Health (NIH), Behavioral Pharmacology, 1995. Ph.D., University of Florida, Experimental Psychology, 1992. Postdoctoral Fellowship, Johns Hopkins University, Behavioral Pharmacology, 1992. M.S., University of Florida, Clinical Psychology, 1987. B.A., Oberlin College, Psychology, 1983. Expertise and Research InterestsBehavioral neuroscience of substance use disorders and treatment:
- Pharmacological and environmental determinants of drug seeking behavior, using choice progressive ratio procedures and behavioral economic analysis
- Investigation of brain function using PET, MR Spectroscopy, Functional MRI, and EEG in substance abusers
- Role of the endogenous opioid system, especially mu-receptors, in mediating the reinforcing and dependence-producing effects of opioids and other drugs, and in promoting the clinical efficacy of pharmacotherapy (e.g., preventing drug self-administration and withdrawal signs/symptoms)
- Development of human laboratory procedures for evaluating new analgesics and medications for treating substance use and co-occurring disorders
Factors related to vulnerability to substance abuse and relapse:
- Individual differences related to the etiology and course of substance use disorders (e.g., initiation of drug-taking and treatment outcome), including genetic polymorphisms
- Biobehavioral markers (e.g., motor activity, risk-taking, impulsivity, and aggressiveness) Other ExpertiseAcademic Experience:
- Editorial Board, Experimental and Clinical Psychopharmacology (2001-2005)
- Ad hoc reviewer for Experimental and Clinical Psychopharmacology; Drug and Alcohol Dependence; Psychopharmacology; Behavioral Pharmacology; Pharmacology, Biochemistry and Behavior; Biological Psychiatry; Psychophysiology; Depression and Anxiety; Journal of Pain; Analgesia; Clinical Pharmacokinetics; Behavior Research Methods, Instrumentation and Computers; American Journal of Psychiatry; Archives of Medical Research; Journal of Applied Behavior Analysis
- Membership in College on Problems of Drug Dependence (CPDD); American Psychological Association (APA Fellow, Division 28: Psychopharmacology of Substance Abuse); International Study Group Investigating Drugs as Reinforcers (ISGIDAR), International Harm Reduction Association (IHRA)
Administrative Experience:
- Director, Substance Abuse Research Division, Dept. of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine
- Chief, Human Pharmacology Laboratory, Substance Abuse Research Division, Dept. of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine
- Graduate Officer, Translational Neuroscience Program (TNP), Dept. of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine
- Chair, Promotion and Tenure Committee, Dept. of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine
- Chair, VA Merit Review Neurobiology-A Committee (2007-present)
- Chair, Departmental Review Board, Dept. of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine (2000-2006)
- Research Development Committee, Wayne State University School of Medicine (2001-present)
- CPDD committees on Human Research (1998-2001), Membership (2001-2004), Travel Award/Mentorship (2003-2006) and Program (2006-present)
- VA Merit Review Subcommittee on Mental Health and Substance (2004) and Neurobiology-A (2005-present)
- Chair, NIH Special Review Group for Cognition and Perception Study Section (formerly BBBP-4), 2005
- Special Emphasis Panel, NIH grant review, 2005 Future Research- Laboratory modeling of drug relapse and treatment
1) Mechanisms/processes
* Neurochemical markers of relapse potential
* Effects of stressors
2) Treatments
* Medications
* Contingency management
- Laboratory modeling and treatment of polysubstance abuse
- Laboratory models of drug abuse and harm reduction Industrial Relevance- Medication screening (Phase 1 and 2 for safety, pharmacokinetics and efficacy) and abuse liability
- Development of medications for treatment of polydrug abuse and relapse prevention
- Consultant, ALZA Corporation (2003-2004)
- Consultant, BioDelivery Sciences International, Inc. (2005-present)
- Site investigator, Titan Pharmaceuticals, Inc. (2007-present)
- Consultant, Guidepoint Global Advisors (2007-present) KeywordsCOS Keywords:Clinical Psychology, Drug Abuse Treatment, Drugs Or Drug Abuse, Etiology, Experimental Psychology, MRI, Neuroscience, Pharmacology, Physiology, Psychiatry, Psychophysiology, Substance Abuse, Toxicology.Additional Terms:Drug Abuse, Drug Self-administration, Functional MRI, Human Psychopharmacology, Impulsivity and Delay Discounting, Narcotic Dependence, Opioids, PET Imaging, Risk-taking.MembershipsAmerican Psychological Association Behavioral Pharmacology Society College on Problems of Drug Dependence International Harm Reduction Association International Study Group Investigating Drugs as Reinforcers Phi Beta Kappa Sigma Xi, The Scientific Research Society University of Michigan Substance Abuse Research Center Honors and Awards2007, Fellow,
American Psychological Association, Division 28 (Psychopharmacology and Substance Abuse)
2006-2009,
Neurobiology-A Committee; Chair,
Veterans Affairs Merit Review
2006-2009,
College on Problems of Drug Dependence,
Program Committee
2005-2006,
Career Development Chair Award,
Wayne State University
2003, Travel Award,
American Psychological Association
2003-2006,
College on Problems of Drug Dependence,
Travel Award Committee
2001-2004,
College on Problems of Drug Dependence,
Membership Committee
1998-2001,
College on Problems of Drug Dependence,
Human Research Committee
1994, Travel Award, Committee on Problems of Drug Dependence,
National Institute on Drug Abuse,
National Institutes of Health
1994-1995,
Postdoctoral Intramural Research Training Award Fellowship,
National Institute on Drug Abuse,
National Institutes of Health
1992-1994,
Postdoctoral Research Fellow, USPHS Training Grant T32 DA07209,
National Institute on Drug Abuse,
National Institutes of Health
Previous Positions1996-2003, Assistant Professor,
Wayne State University,
School of Medicine,
Psychiatry & Behavioral Neurosciences,
Substance Abuse Research
1995, Instructor,
Johns Hopkins University,
School of Medicine,
Psychiatry and Behavioral Sciences
1994-1995, Postdoctoral Research Fellow,
National Institutes of Health (NIH),
National Institute on Drug Abuse,
Addiction Research Center
1992-1994, Postdoctoral Research Fellow,
Johns Hopkins University,
Psychiatry
Funding Received- Titan Pharmaceuticals, Inc.:
A Multi-Center Extension Study of Probuphine® in Patients with Opioid Dependence (Site PI),
$5,942 per patient,
2008
to 2009.
- National Institutes of Health (NIH):
Prenatal Cocaine and At-Risk Late Teen Behavior (Co-Invest., 5% effort),
2008
to 2013.
- Titan Pharmaceuticals, Inc.:
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine® in Patients with Opioid Dependence (PRO-805 Site PI),
$14,680 per patient,
2007
to 2008.
- SAMHSA/Center for Substance Abuse Treatment:
Integrated Substance Use and Physical Health Intervention for Recovery (INSPIRE): A Substance Abuse Program for Minority Persons Living with HIV/AIDS (PI),
$2,500,000,
2007
to 2012.
- BioDelivery Sciences International, Inc.:
The Effects of Three Dose Ratios of Fentanyl and Naloxone in Opioid-Dependent Volunteers (PI),
$22,718 per subject,
2006
to 2007.
- National Institutes of Health (NIH):
Reducing Cocaine/Heroin Abuse with SR-Amphetamine and Buprenorphine (PI),
$750,000,
2006
to 2009.
- National Institutes of Health (NIH):
Neurochemistry of Opiate Abuse Risk in Chronic Pain (Coinvest., 10% effort),
$182,015,
2006
to 2011.
- Wayne State University:
Brain Chemistry in Opioid Dependent Volunteers Using MR Spectroscopy (PI),
$19,000,
2005
to 2006.
- NIDA:
Genetics Supplement to Biobehavioral Studies of Opioid Drug-Seeking Behavior (PI),
$123,000,
2004
to 2007.
- National Institutes of Health (NIH):
Pharmacological Studies of Opioid Dependence in Humans (Project PI, 10% effort),
$400,000,
2003
to 2007.
- National Institutes of Health (NIH):
Biobehavioral Studies of Opioid Drug-Seeking Behavior (PI, 45% effort),
$1,400,000,
2003
to 2009.
- ALZA Corporation:
Abuse Liability study (PI, 35% effort),
2003
to 2004.
- National Institutes of Health (NIH):
Prenatal Cocaine Exposure and School Age Outcome (Coinv. 5% effort),
2003
to 2007.
- National Institute on Drug Abuse:
FMRI Studies of Tobacco Craving (Coinvest., 25% effort),
2001
to 2004.
- National Institutes of Health (NIH):
Early drug use: Susceptibility and Protection (Consultant),
1998
to 2003.
- National Institutes of Health (NIH):
Individual Differences in Biobehavioral Drug Response (Coinv. 5% effort),
1997
to 2000.
- National Institute on Drug Abuse:
Behavioral Studies with Methadone Clients (PI, 50% effort),
1997
to 2003.
- National Institute on Drug Abuse:
Pharmacological Studies of Buprenorphine (Coinv., 20% effort),
1996
to 2003.
Publications- Greenwald MK, Opioid abstinence reinforcement delays heroin lapse during buprenorphine dose tapering, J Appl Behav Anal, In Press, 2008
- Moody DE, An enantiomer selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine and liver microsomes, J Anal Toxicol, In Press, 2008
- Greenwald MK, Behavioral economic analysis of drug preference using Multiple Choice Procedure data, Drug Alcohol Depend, 93, 103-110, 2008
- Roddy J, Greenwald MK (2008) Economic analysis of income and expenditures in heroin abusing research volunteers, Substance Use Misuse, In Press
- Greenwald MK, Johanson, CE, Bueller J, Chang Y, Moody DE, Kilbourn MR, Koeppe RA, Zubieta JK, Buprenorphine duration of action: mu-opioid receptor availability, pharmacokinetic and behavioral indices, Biol Psychiatry, 61, 101-110, 2007
- Chiodo LM, Blood lead levels and specific attention effects in young children, Neurotoxicol Teratol, 29, 538-546, 2007
- Steinmiller CL, Greenwald MK, Factors associated with non-medical use of prescription opioids among heroin abusing research volunteers, Exp Clin Psychopharmacol, 15, 492-500, 2007
- Steinmiller CL, Greenwald MK (2007) Factors associated with non-medical use of prescription opioids among heroin abusing research volunteers, Exp Clin Psychopharmacology, 15, 492-500
- Greenwald MK, Steinmiller CL (2007) Imaging opioid receptors: applications to substance use disorders., In Dean R, Negus SS, Bilsky E (eds), Opioid Receptors and Antagonists: From Bench to Clinic, New York, Humana Press, In Press (bookchapter)
- Greenwald MK, Hursh SR, Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of pre-session drug supply and unit price, Drug Alcohol Depend, 85, 35-48, 2006
- Reilly MP, Greenwald MK, Johanson CE, The Stoplight Task: a procedure for measuring risk-taking behavior in humans, Psychol Record, 56, 191-204, 2006
- Roehrs TA, Hyde M, Blaisdell B, Greenwald MK, Roth T, Sleep loss and REM sleep loss are hyperalgesic, Sleep, 29, 145-151, 2006
- Greenwald MK, Early impact of methadone induction for heroin dependence: differential efects of two dose sequences in a randomized controlled study, Exp Clin Psychopharmacol, 14, 52-67, 2006
- Greenwald MK (2006) Human experimental therapeutic models in opioid dependence: translational research advances and implications. In McKenna CR (eds), Trends in Substance Abuse Research, New York, Nova Science Publishers, Inc., 1-55 pages (bookchapter)
- Greenwald MK, Opioid craving and seeking behavior in physically dependent volunteers: effects of acute withdrawal and drug reinforcement opportunity, Exp Clin Psychopharmacol, 13, 3-14, 2005
- Greenwald MK, Roehrs TA, Mu-opioid self-administration versus passive administration in heroin abusers produces differential EEG activation, Neuropsychopharmacology, 30, 212-221, 2005
- Marco AP, Greenwald MK, Higgins MS, A preliminary study of 24-hour post-Cesarean patient-controlled analgesia: postoperative pain reports and morphine requests/utilization are greater in abstaining smokers than non-smokers, Medical Science Monitor, 11, 255-261, 2005
- Roehrs TA, Greenwald MK, Roth T, Risk-taking behavior: effects of ethanol, caffeine and basal sleepiness, Sleep, 27, 887-893, 2004
- Greenwald MK, Effects of opioid dependence and tobacco use on ventilatory response to progressive hypercapnia, Pharmacol Biochem Behav, 77, 39-47, 2004
- Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta JK, Effects of buprenorphine maintenance dose on mu-opioid receptor binding potential, plasma concentration, and antagonist blockade in heroin-dependent volunteers, Neuropsychopharmacology, 28, 2000-2009, 2003
- Alessi SM, Greenwald MK, Johanson CE, The prediction of individual differences in response to d-amphetamine in healthy adults, Behav Pharmacol, 14, 19-32, 2003
- Greenwald MK, Schuh KJ, Stine S, Transferring heroin-dependent outpatients stabilized on moderate-dose methadone to the buprenorphine sublingual tablet: a preliminary study, Amer J Addictions, 12, 365-374, 2003
- Stine SM, Greenwald MK, Kosten TR (2003) Ultra rapid opiate detoxification., Principles of Addiction Medicine, 3rd edition, Maryland, American Society of Addiction Medicine, 668-669 pages (bookchapter)
- Stine SM, Greenwald MK, Kosten TR (2003) Pharmacologic interventions for opioid addiction, Principles of Addiction Medicine, 3rd edition, Maryland, American Society of Addiction Medicine, 735-748 pages (bookchapter)
- Greenwald MK, Schuh KJ, Hopper J, Schuster CR, Johanson CE, Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans, Psychopharmacology, 160, 344-352, 2002
- Greenwald MK, Heroin craving and drug use in opioid-maintained volunteers: effects of methadone dose variations, Exp Clin Psychopharmacol, 10, 39-46, 2002
- Greenwald MK, Johanson CE, Behavioral measurement of thermal pain sensitivity in humans: effects of stimulus intensity and instructions, Exp Clin Psychopharmacol, 9, 209-214, 2001
- Zubieta JK, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, Koeppe RA, Schuster CR, Johanson, CE, Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study, Neuropsychopharmacology, 23, 326-334, 2000
- Greenwald MK, Stitzer ML, Antinociceptive, subjective and behavioral effects of smoked marijuana in humans, Drug Alcohol Depend, 59, 261-275, 2000
- Greenwald MK, Johanson CE, Schuster CR, Opioid reinforcement in heroin-dependent volunteers during buprenorphine maintenance, Drug Alcohol Depend, 56, 191-203, 1999
- Greenwald MK, Bradley MM, Cuthbert BN, Lang PJ, Startle potentiation: shock sensitization, aversive learning, and affective picture modulation, Behav Neurosci, 112, 1069-1079, 1998
- Greenwald MK, Schuster CR, Johanson CE, Jewell J, Automated measurement of motor activity in human subjects: effects of repeated testing and d-amphetamine, Pharmacol Biochem Behav, 59, 59-65, 1998
- Greenwald MK, Stitzer ML, Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine, Drug Alcohol Depend, 53, 17-30, 1998
- Greenwald MK, Stitzer ML, Haberny KA, Human pharmacology of the opioid neuropeptide, dynorphin A(1-13), J Pharmacol Exp Ther, 281, 1154-1163, 1997
- Greenwald MK, June HL, Stitzer ML, Marco AP, Comparative clinical pharmacology of short-acting mu opioids in drug abusers, J Pharmacol Exp Ther, 277, 1228-1236, 1996
- Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, Stitzer ML, Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans, J Pharmacol Exp Ther, 276, 449-459, 1996
- Schuster CR, Greenwald MK, Johanson CE, Heishman SJ, Measurement of drug craving during naloxone-precipitated withdrawal in methadone-maintained volunteers, Exp Clin Psychopharmacol, 3, 424-431, 1995
- Azorlosa JL, Greenwald MK, Stitzer ML, Marijuana smoking: effects of varying puff volume and breathhold duration, J Pharmacol Exp Ther, 272, 560-569, 1995
- Azorlosa JL, Stitzer ML, Greenwald MK, Opioid physical dependence development: effects of single versus repeated morphine pretreatments and of subjects' opioid exposure history, Psychopharmacology, 114, 71-80, 1994
Profile DetailsIndividual Expertise profile of Mark Kenneth Greenwald, Copyright Mark Kenneth Greenwald. © COS Expertise TM, 2008, ProQuest LLC All rights reserved. |